Role of histone deacetylase 2 and its posttranslational modifications in cardiac hypertrophy

키워드

참고문헌 (60)

1. Eom GH, "Posttranslational modifications of histone deacetylases: implications for cardiovascular diseases", Pharmacol Ther, 143, pp.168~180 (2014)
2. Frey N, "Cardiac hypertrophy: the good, the bad, and the ugly", Annu Rev Physiol, 65, pp.45~79 (2003)
3. Hill JA, "Cardiac plasticity", N Engl J Med, 358, pp.1370~1380 (2008)
4. Hunter DJ, "Noncommunicable diseases", N Engl J Med, 369, pp.1336~1343 (2013)
5. Dimmeler S, "Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation", Nature, 399, pp.601~605 (1999)
6. Beg AA, "Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation", Mol Cell Biol, 13, pp.3301~3310 (1993)
7. Maudsley S, "The beta(2)-adrenergic receptor mediates extracellular signalregulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor", J Biol Chem, 275, pp.9572~9580 (2000)
8. Zhang CL, "Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy", Cell, 110, pp.479~488 (2002)
9. 박철우, "Cellular ubiquitin pool dynamics and homeostasis", BMB Reports, 47(9), pp.475~482 (2014), 생화학분자생물학회
10. Santos-Rosa H, "Mechanisms of P", CAF auto-acetylation, 2003, pp.31, 4285~4292
11. Gu W, "Activation of p53 sequence-specific DNA binding by acetylation of the p53C-terminal domain", Cell, 90, pp.595~606 (1997)
12. Evans PM, "Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation", J Biol Chem, 282, pp.33994~34002 (2007)
13. Driessen HP, "The mechanism of N-terminal acetylation of proteins", CRC Crit Rev Biochem, 18, pp.281~325 (1985)
14. Laherty CD, "Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression", Cell, 89, pp.349~356 (1997)
15. Nagy L, "Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase", Cell, 89, pp.373~380 (1997)
16. Fischle W, "Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3and SMRT", N-CoR, 2002, pp.9, 45~57
17. Jones P, "Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases", Bioorg Med Chem Lett, 18, pp.1814~1819 (2008)
18. McKinsey TA, "Activation of the myocyte enhancer factor-2 transcription factor by calcium", calmodulin-dependent protein kinase-stimulated binding of 14-3-3 to histone deacetylase 5, 2000, pp.97, 14400~14405
19. Eom GH, "Regulation of acetylation of histone deacetylase 2 by p300", CBP-associated factor, Circ Res, pp.2014, 114[DOI]
20. Nebbioso A, "Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes", EMBO Rep, 10, pp.776~782 (2009)
21. Chang S, "Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development", Mol Cell Biol, 24, pp.8467~8476 (2004)
22. Vega RB, "Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5", Mol Cell Biol, 24, pp.8374~8385 (2004)
23. Hubbert C, "HDAC6 is a microtubule-associated deacetylase", Nature, 417, pp.455~458 (2002)
24. Montgomery RL, "Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility", Genes Dev, 21, pp.1790~1802 (2007)
25. Azechi T, "Trichostatin A, an HDAC class I", II inhibitor, promotes pi-induced vascular calcification via up-regulation of the expression of alkaline phosphatase, 2013, pp.20, 538~547
26. Johnstone RW, "Histone-deacetylase inhibitors: novel drugs for the treatment of cancer", Nat Rev Drug Discov, 1, pp.287~299 (2002)
27. Kee HJ, "Trichostatin A prevents neointimal hyperplasia via activation of Kruppel like factor 4", Vascul Pharmacol, 55, pp.127~134 (2011)
28. Cincarova L, "New perspectives of valproic acid in clinical practice", Expert Opin Investig Drugs, 22, pp.1535~1547 (2013)
29. Liu F, "Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin", J Mol Cell Cardiol, 45, pp.715~723 (2008)
30. Zhao TC, "Inhibition of histone deacetylases triggers pharmacologic preconditioning effects against myocardial ischemic injury", Cardiovasc Res, 76, pp.473~481 (2007)
31. Lee TM, "Inhibition of histone deacetylase on ventricular remodeling in infarcted rats", Am J Physiol Heart Circ Physiol, 293, pp.968~977 (2007)
32. Granger A, "Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice", FASEB J, 22, pp.3549~3560 (2008)
33. Lee HA, "Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension", Circ Res, 112, pp.1004~1012 (2013)
34. Cho YK, "Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats", Circ J, 74, pp.760~770 (2010)
35. Eom GH, "Casein kinase-2alpha1 induces hypertrophic response by phosphorylation of histone deacetylase 2 S394 and its activation in the heart", Circulation, 123, pp.2392~2403 (2011)
36. Kee HJ, "Inhibition of histone deacetylation blocks cardiac hypertrophy induced by angiotensin II infusion and aortic banding", Circulation, 113, pp.51~59 (2006)
37. Kook H, "Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop", J Clin Invest, 112, pp.863~871 (2003)
38. Kong Y, "Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy", Circulation, 113, pp.2579~2588 (2006)
39. Kee HJ, "Activation of histone deacetylase 2 by inducible heat shock protein 70 in cardiac hypertrophy", Circ Res, 103, pp.1259~1269 (2008)
40. Gallo P, "Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure", Cardiovasc Res, 80, pp.416~424 (2008)
41. Trivedi CM, "Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity", Nat Med, 13, pp.324~331 (2007)
42. Monteforte N, "Genetics and arrhythmias: diagnostic and prognostic applications", Rev Esp Cardiol, 65, pp.278~286 (2012)
43. Ismat FA, "Homeobox protein Hop functions in the adult cardiac conduction system", Circ Res, 96, pp.898~903 (2005)
44. Trivedi CM, "Hopx and Hdac2 interact to modulate Gata4 acetylation and embryonic cardiac myocyte proliferation", Dev Cell, 19, pp.450~459 (2010)
45. Zhu W, "Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness", Circ Res, 105, pp.1240~1247 (2009)
46. Kee HJ, "Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy", J Mol Cell Cardiol, 47, pp.770~780 (2009)
47. Liao X, "Kruppel-like factor 4regulates pressure-induced cardiac hypertrophy", J Mol Cell Cardiol, 49, pp.334~338 (2010)
48. Levy L, "Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction", Mol Cell Biol, 24, pp.3404~3414 (2004)
49. Chen LF, "Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB", EMBO J, 21, pp.6539~6548 (2002)
50. Ito A, "MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation", EMBO J, 21, pp.6236~6245 (2002)
51. Ito K, "Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression", J Exp Med, 203, pp.7~13 (2006)
52. Watamoto K, "Altered interaction of HDAC5 with GATA-1 during MEL cell differentiation", Oncogene, 22, pp.9176~9184 (2003)
53. Choudhary C, "Lysine acetylation targets protein complexes and co-regulates major cellular functions", Science, 325, pp.834~840 (2009)
54. Nott A, "S-Nitrosylation of histone deacetylase 2 induces chromatin remodelling in neurons", Nature, 455, pp.411~415 (2008)
55. Colussi C, "HDAC2blockade by nitric oxide and histone deacetylase inhibitors reveals a common target in Duchenne muscular dystrophy treatment", Proc Natl Acad Sci U S A, 105, pp.19183~19187 (2008)
56. Malhotra D, "Denitrosylation of HDAC2 by targeting Nrf2 restores glucocorticosteroid sensitivity in macrophages from COPD patients", J Clin Invest, 121, pp.4289~4302 (2011)
57. Brandl A, "Dynamically regulated sumoylation of HDAC2 controls p53 deacetylation and restricts apoptosis following genotoxic stress", J Mol Cell Biol, 4, pp.284~293 (2012)
58. Galasinski SC, "Phosphatase inhibition leads to histone deacetylases 1 and 2 phosphorylation and disruption of corepressor interactions", J Biol Chem, 277, pp.19618~19626 (2002)
59. Adenuga D, "Protein kinase CK2-mediated phosphorylation of HDAC2 regulates co-repressor formation, deacetylase activity and acetylation of HDAC2by cigarette smoke and aldehydes", Arch Biochem Biophys, 498, pp.62~73 (2010)
60. Adenuga D, "Histone deacetylase 2 is phosphorylated, ubiquitinated, and degraded by cigarette smoke", Am J Respir Cell Mol Biol, 40, pp.464~473 (2009)

관련 논문AI추천